Personalized blood thinners for lung clots
Part of Heart & circulation, Lungs & breathing clinical trials.
This study tests personalized blood thinner treatments for people with blood clots in their lungs. It looks for patients who are older, have kidney problems, or have cancer, to see if adjusting the treatment helps them more.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a confirmed blood clot in your lung (pulmonary embolism)
- You must be 75 or older, have reduced kidney function, or have active cancer
- You cannot have already started blood thinners for this condition
- You must not have severe liver disease or a high bleeding risk
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how to quickly and safely rule out blood clots in the lungs of cancer patients who come to the emergency room. It aims to help doctors make faster decisions and avoid unnecessary treatments for people with cancer.
This trial tests if apixaban, a blood thinner pill, can prevent dangerous blood clots in people with advanced lung cancer who are receiving outpatient chemotherapy or other systemic treatments. It aims to reduce the risk of venous thromboembolism (blood clots in veins) during cancer therapy.
This real-world study compares different treatment approaches for pulmonary embolism (PE)—a serious blood clot in the lung arteries—in patients who are stable but at intermediate-to-high risk of complications. The goal is to understand which treatments work best and safest in everyday practice.
This trial looks at how long people need blood-thinning medicine after a serious blood clot in the lungs. It might help doctors find the best treatment length for each person.
This study looks at how the body processes a certain type of blood thinner (Xa factor inhibitors) to help doctors find the right dose for each person. If you have a blood clot in your lungs and are on long-term treatment, this trial might help improve your care.
This trial compares three treatments for an intermediate-high risk pulmonary embolism: a minimally invasive clot removal procedure (embolectomy), a low-dose clot-dissolving medication, or standard blood thinning (heparin). The goal is to see which approach works best to prevent worsening while reducing bleeding risks.
Hear when a new Pulmonary Thromboembolisms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.